BioNTech und OncoC4 starten zulassungsrelevante Phase-3-Studie mit BNT316/ONC-392-Programm bei metastasiertem, nicht-kleinzelligem Lungenkarzinom
29 juin 2023 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie für nicht-kleinzelliges Lungenkarzinom ist ein wichtiger erster Schritt in BioNTechs und OncoC4s strategischer Kollaboration, die im März 2023...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
29 juin 2023 06h45 HE
|
BioNTech SE
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
08 juin 2023 07h00 HE
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
05 juin 2023 06h45 HE
|
Synlogic, Inc.
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...
Cingulate to Present at 13th Annual LD Micro Invitational
25 mai 2023 15h55 HE
|
Cingulate Inc.
KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
10 mai 2023 16h15 HE
|
Cingulate Inc.
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS...
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
02 mai 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
A total of 652 children, ages 2 to 5, were enrolled in the studyTopline data expected in the third quarterAtopic dermatitis (AD) affects approximately 26 million adults and children in the United...
Cingulate to Participate in Benzinga All Live Access Event
14 avr. 2023 14h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
20 mars 2023 06h55 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
07 mars 2023 03h00 HE
|
AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...